Navigation Links
Sorafenib Slows Growth of Some Leukemias
Date:2/1/2008

Drug shows potential for patients with specific gene mutations, researchers find

FRIDAY, Feb. 1 (HealthDay News) -- The drug sorafenib shows promise in the treatment of people with acute myeloid leukemia who have specific gene mutations, say U.S. researchers.

Previous research has shown that sorafenib -- currently used to treat kidney and liver cancer -- is effective against acute myeloid leukemia cells that have internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene, according to background information in the study.

Researchers at the University of Texas M.D. Anderson Cancer Center in Houston looked at sorafenib's effect on leukemia cells that express either the common or mutant copies of FLT3. They also gave the drug to mice with leukemia cells with known FLT3 mutations and to leukemia patients with and without the FLT3 mutation.

Sorafenib slowed growth and induced cell death in the FLT3 mutant leukemia cells and increased survival of the mice with FLT3 mutant leukemia. The drug also reduced the percentage of leukemia cells in the blood and marrow of leukemia patients with the FLT3 mutation but not in leukemia patients without the mutation.

"Our findings imply that sorafenib is a potent anti-leukemic agent in patients with FLT3-ITD mutant [acute myeloid leukemia], a form of [the disease] that responds poorly to traditional chemotherapy," the study authors concluded.

The findings were published in the Jan. 29 issue of the Journal of the National Cancer Institute.

More information

The American Cancer Society has more about acute myeloid leukemia.



-- Robert Preidt



SOURCE:Journal of the National Cancer Institute, news release, Jan. 29, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Health Insurance Premium Growth Slows for Fourth Straight Year
2. Philanthropic Giving for Health Care Slows in 2006 in both U.S. and Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
3. Drug slows prostate tumor growth by keeping vitamin A active
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. High pollution linked to poor lung function growth in children in Mexico City
6. Researchers develop long-lasting growth hormone
7. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
8. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
9. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
10. AWT Management Announce Aggressive Growth and Acquisition Strategy
11. Cynosure to Present at the Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sorafenib Slows Growth of Some Leukemias
(Date:6/28/2017)... ... June 28, 2017 , ... Anyone with a remote control has seen the never-ending twists on ... the flipper will get rich in no time. But what about the buyers of ... for the buyer of a flipped house. An email recently sent to Gary Case ...
(Date:6/28/2017)... , ... June 28, 2017 , ... David B. Sosin, a founding partner ... took over the post of 2nd Vice President for the Illinois State Bar Association ... as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served in ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces ... of the award winning television series, scheduled to broadcast fourth quarter 2017. American Farmer ... as a regional supplier of garden pea seed. As demand grew, the small company ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, a Cincinnati ... to insurance assistance and financial planning services, is announcing the commencement of a ... the region facing financial crisis. , Matthew 25: Ministries (M25M) is an international ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
Breaking Medicine Technology: